Facovit coated tablets №30


Manufacturer: Ukraine

Prevention and treatment of the initial stages of cataract formation in the lens in the elderly or in chronic low-intensity radiation exposure.



Facovit Composition
active substances: the drug consists of two types of tablets:

1 gastro-soluble tablet contains L-glutamic acid 200 mg, glycine 100 mg, pyridoxine hydrochloride 25 mg;

excipients: potato starch, calcium stearate, lactose monohydrate;

1 enteric coated tablet contains 200 mg of L-cysteine, 175 mg of ascorbic acid;

excipients: potato starch, calcium stearate, lactose monohydrate, oidragit L-100-55, macrogol 4000, tropeolin 0, talc.

Facovit Dosage form
Gastro-soluble tablets and enteric-coated tablets.

Main physical and chemical properties: gastro-soluble tablets of white or almost white color, flat-cylindrical, with a line and a facet; film-coated tablets, enteric-coated from yellow-orange to brown, biconvex. Marbling is allowed on the surface of the tablets. Two layers are visible in cross section.

Facovit Pharmacological group
Means used in ophthalmology. Trophic means.

ATC code S01X A.

Pharmacological properties


Means for regulation of metabolic processes in the lens, which has anti-radical and detoxifying properties.

Glutathione tripeptide is synthesized in the lens of the eye from glutamic acid, glycine and cysteine ​​with the participation of adenosine triphosphate (ATP), which is a central link in the enzymatic system of antioxidant protection of proteins and neutralization of toxic metabolites. The phosphorylated form of pyridoxine hydrochloride (pyridoxal phosphate) provides transport of these amino acids into the lens through the capsule. Ascorbic acid acts as a regulator of redox processes in the lens, is involved in the restoration of disulfide bonds.

The drug reduces the intensity of free radical processes in the lens, thereby reducing the formation of crosslinks and polymerization of its proteins, which is manifested in the slowing down or suspension of clouding of the lens.


Not studied.

Prevention and treatment of the initial stages of cataract formation in the lens in the elderly or with chronic radiation exposure of low intensity.

Hypersensitivity to the components of the drug, severe hepatic / renal failure, nephrotic syndrome, fever, irritability with pronounced psychotic reactions, gastric / duodenal ulcer in the acute stage, hematopoietic diseases with anemia / leukopenia.

Interaction with other drugs and other types of interaction
Reduces the toxicity of anticonvulsants, neuroleptics, antidepressants. When combined with hypnotics, the effect of inhibiting the central nervous system is enhanced. Increases the disposal and total clearance of ethyl alcohol, the concentration in the blood of salicylates, sulfonamides, benzylpenicillin and tetracyclines; reduces – oral contraceptives. Weakens the anticoagulant effect of coumarin and heparin derivatives. The effectiveness of the drug is reduced by isoniazid, cycloserine, penicillamine. When co-administered with levodopa, concomitant use of dopa decarboxylase inhibitors is required, as the effect of levodopa is inhibited.